Horizon Pays $35M For AstraZeneca's Arthritis Drug Rights
Horizon Pharma Inc. said Tuesday that it would buy the U.S. rights to make and sell AstraZeneca PLC's Vimovo for $35 million up front, less than a month after the pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article